The EDICT study, employing diabetes medications (GLP-1 receptor agonist, pioglitazone, metformin) that correct the basic underlying pathophysiologic defects present in type 2 diabetes, convincingly demonstrated that combination therapy produces a greater and more durable reduction in HbA1c than the treat-to-fail approach using diabetes medications (sulfonylureas, metformin, insulin) that do not correct the basic metabolic and cellular defects (insulin resistance and beta-cell dysfunction) present in type 2 diabetes patients
(Basit Anlatm) Yalarn enerji olarak yaklabilmesi iin hcrenin iindeki frna, yani Mitokondri 'ye girmesi gerekir
Canadian Medical Association Journal 172(7): 873
This infusion helps combat oxidative stress, supports liver function and helps brighten the complexion naturally while supporting energy, focus, and healthy aging
When combination therapy might be justified, and when it absolutely should not happen